<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TISSEEL- fibrinogen human and thrombin human 
			 </strong><br>Baxter Healthcare Corporation<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use TISSEEL safely and
        effectively. See full prescribing information for TISSEEL.<br><br>TISSEEL [Fibrin Sealant]<br>For Topical Use Only<br>Frozen solution and lyophilized
        powder for solution for topical application<br>Initial U.S. Approval: 1998</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Adverse Reactions; Post Marketing (<a href="#i4i_section_id_209c0f34-db97-4340-aec9-f4bd8c853424">6.3</a>)
                                                                  11/2009 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul>
<li>
<span class="Bold">Hemostasis</span>: TISSEEL is a
                                        fibrin sealant indicated for use as an adjunct to hemostasis
                                        in surgeries involving cardiopulmonary bypass and treatment
                                        of blunt or penetrating splenic injuries when control of
                                        <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> by conventional surgical techniques, including
                                        suture, ligature, and cautery, is ineffective or
                                        impractical. TISSEEL is a hemostatic agent that may be used
                                        in fully heparinized patients undergoing cardiopulmonary
                                        bypass (<a href="#i4i_section_id_e4566ecb-d453-439e-9650-abff7eaf67f4">1.1</a>)</li>
<li>
<span class="Bold">Sealing</span>: TISSEEL is a
                                        fibrin sealant indicated as an adjunct to standard surgical
                                        techniques (such as suture and ligature) to prevent leakage
                                        from colonic anastomoses following the reversal of temporary
                                        colostomies (<a href="#i4i_section_id_d52905e4-7e90-4d62-8113-3b2d20554769">1.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">For Topical Use Only. Do Not Inject
                                            (<a href="#i4i_dosage_admin_id_648c2716-0763-491e-9896-83df060c12d4">2</a>)</span> </p>
<p class="Highlighta">TISSEEL Kit (Freeze-Dried) requires
                                    reconstitution prior to use (<a href="#i4i_section_id_5cd272c6-da50-46ee-b624-7c7d951a61dd">2.1</a>) </p>
<p class="Highlighta">TISSEEL Pre-filled
                                    Syringe (Frozen) requires thawing prior to use (<a href="#i4i_section_id_c0e7aacb-281b-4a73-ac5d-18b6ce06b345">2.2</a>) </p>
<p class="Highlighta">Apply TISSEEL as a
                                    thin layer (<a href="#i4i_section_id_58eae001-4926-419b-ad77-d0f251206e68">2.3</a>, <a href="#i4i_section_id_b1a55fd6-28c1-46f0-8f3c-272f442f585c">5.2</a>) </p>
<p class="Highlighta">Vials and pre-filled
                                    syringes are for single use only. Discard unused contents
                                        (<a href="#i4i_section_id_58eae001-4926-419b-ad77-d0f251206e68">2.3</a>) </p>
<p class="Highlighta">To ensure adequate
                                    mixing, expel and discard the first several drops from the
                                    cannula in cases where very small volumes (1-2 drops) are
                                    applied (<a href="#i4i_section_id_58eae001-4926-419b-ad77-d0f251206e68">2.3</a>) </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">TISSEEL Kit (Freeze-Dried) is supplied as 2 mL, 4 mL
                                    and 10 mL (total volume) pack sizes with and without the
                                    DUPLOJECT System (<a href="#i4i_section_id_0e83f45d-79a4-4325-b4cc-40edb5cb7978">3.1</a>). </p>
<p class="Highlighta">TISSEEL Pre-filled
                                    Syringe (Frozen) is supplied as 2 mL, 4 mL and 10 mL (total
                                    volume) pack sizes with the DUO Set (<a href="#i4i_section_id_0e83f45d-79a4-4325-b4cc-40edb5cb7978">3.1</a>). </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Do not inject directly into the circulatory system or into
                                        highly vascularized tissue (<a href="#i4i_section_id_b31b17a2-f4c7-42d5-b496-1bb088cbc3fb">4.1, </a><a href="#i4i_section_id_da1e38ce-e463-4a5b-bbd4-637b51720a5c">5.3)</a>
</li>
<li>Do not use in individuals with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to
                                        aprotinin (<a href="#i4i_section_id_5b895abf-fa57-450c-8d28-8f650d8aab57">4.2</a>, <a href="#i4i_section_id_b37d90e7-1ad5-421f-86b7-210babca1e74">5.1</a>, <a href="#i4i_section_id_26e45906-641b-4b8a-bff4-3f7c87c08981">6.1</a>)</li>
<li>Do not use for the treatment of severe or brisk arterial
                                        or venous <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#i4i_section_id_69caf6f5-999d-4cae-ac6b-2f19208074f2">4.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>TISSEEL contains aprotinin, a monomeric polypeptide known
                                        to be associated with <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> (<a href="#i4i_section_id_5b895abf-fa57-450c-8d28-8f650d8aab57">4.2, </a><a href="#i4i_section_id_b37d90e7-1ad5-421f-86b7-210babca1e74">5.1,</a><a href="#i4i_section_id_26e45906-641b-4b8a-bff4-3f7c87c08981">6.1)</a>
</li>
<li>Air or gas <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> has occurred with the use of spray
                                        devices employing pressure regulator to administer fibrin
                                        sealants. This event appears to be related to the use of the
                                        spray device at higher than recommended pressures and in
                                        close proximity to the surface of the tissue (<a href="#i4i_section_id_b1a55fd6-28c1-46f0-8f3c-272f442f585c">5.2</a>)</li>
<li>Exposure to solutions containing alcohol, iodine or heavy
                                        metals may cause TISSEEL to be denatured (<a href="#i4i_section_id_b1a55fd6-28c1-46f0-8f3c-272f442f585c">5.2</a>)</li>
<li>Apply only as thin layer. Excess clot thickness may delay
                                        the natural <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing process. (<a href="#i4i_dosage_admin_id_648c2716-0763-491e-9896-83df060c12d4">2,</a><a href="#i4i_section_id_b1a55fd6-28c1-46f0-8f3c-272f442f585c">5.2)</a>
</li>
<li>Caution should be exercised to minimize the risk of
                                        inadvertent intravascular application when using TISSEEL in
                                        cardiopulmonary bypass surgeries (<a href="#i4i_section_id_b31b17a2-f4c7-42d5-b496-1bb088cbc3fb">4.1,</a><a href="#i4i_section_id_da1e38ce-e463-4a5b-bbd4-637b51720a5c"> 5.3,</a><a href="#i4i_section_id_209c0f34-db97-4340-aec9-f4bd8c853424">6.3)</a>
</li>
<li>Safety has not been evaluated in neurosurgical procedures
                                            (<a href="#i4i_section_id_e9d9d7e4-c1c0-4e84-8214-32fdb00431f8">5.4</a>)</li>
<li>The safety and effectiveness of the combined use of
                                        TISSEEL with other biocompatible materials has not been
                                        evaluated in controlled clinical trials (<a href="#i4i_section_id_e9d9d7e4-c1c0-4e84-8214-32fdb00431f8">5.4</a>, <a href="#i4i_section_id_209c0f34-db97-4340-aec9-f4bd8c853424">6.3</a>)</li>
<li>This product is made from pooled human plasma which may
                                        contain infectious agents (<a href="#i4i_section_id_d60755c3-08ff-400e-a3ae-83907fcefd74">5.5</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Anaphylactic and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been
                                    reported. No adverse events of this type were reported during
                                    clinical trials (<a href="#i4i_section_id_b37d90e7-1ad5-421f-86b7-210babca1e74">5.1</a>, <a href="#i4i_section_id_26e45906-641b-4b8a-bff4-3f7c87c08981">6.1</a>, <a href="#i4i_section_id_209c0f34-db97-4340-aec9-f4bd8c853424">6.3</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS,
                                        contact Baxter Healthcare Corporation at 1-866-888-2472 or
                                        FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Oxycellulose containing preparations may reduce the
                                    efficacy of TISSEEL and should not be used as carrier materials
                                        (<a href="#i4i_interactions_id_d9d2ede8-72f1-4937-bc55-5a8b53da7fca">7</a>) </p></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 9/2009</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Hemostasis</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Sealing</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Preparation of TISSEEL Kit (Freeze-Dried)</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Preparation of TISSEEL Pre-Filled Syringe (Frozen)</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Method of Application</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h2><a href="#section-3.1" class="toc">3.1 Presentations and Pack Sizes</a></h2>
<h2><a href="#section-3.2" class="toc">3.2 Package Contents</a></h2>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 Intravascular Application</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Aprotinin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h2><a href="#section-4.3" class="toc">4.3 Arterial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/Allergic/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Application Precautions</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Use in Cardiopulmonary Surgery</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Use in Neurosurgical Procedures</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> Risk from Human Plasma</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Overall Adverse Reactions</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Post Marketing</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-10" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-10.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-10.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-10.4" class="toc">12.4 Other Clinical Pharmacology Information</a></h2>
<h1><a href="#section-11" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-12.1" class="toc">14.1 Cardiac Surgery</a></h2>
<h2><a href="#section-12.2" class="toc">14.2 Cardiac Reoperations</a></h2>
<h2><a href="#section-12.3" class="toc">14.3 Splenectomy</a></h2>
<h2><a href="#section-12.4" class="toc">14.4 Colostomy Closure</a></h2>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_7cf45276-fd18-42eb-871d-bf11682ec655"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e4566ecb-d453-439e-9650-abff7eaf67f4"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Hemostasis</h2>
<p class="First">TISSEEL is a fibrin sealant indicated for use as an
                                    adjunct to hemostasis in surgeries involving cardiopulmonary
                                    bypass and treatment of blunt or penetrating splenic injuries
                                    when control of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> by conventional surgical techniques,
                                    including suture, ligature, and cautery, is ineffective or
                                    impractical. TISSEEL is a hemostatic agent that may be used in
                                    fully heparinized patients undergoing cardiopulmonary
                                    bypass.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d52905e4-7e90-4d62-8113-3b2d20554769"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Sealing</h2>
<p class="First">TISSEEL is a fibrin sealant indicated as an adjunct to
                                    standard surgical techniques (such as suture and ligature) to
                                    prevent leakage from colonic anastomoses following the reversal
                                    of temporary colostomies.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_648c2716-0763-491e-9896-83df060c12d4"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">FOR TOPICAL USE ONLY – DO NOT
                                INJECT.</span></p>
<p>The required dose of TISSEEL depends on the size of
                            the surface to be covered. The approximate surface areas covered by each
                            package size of TISSEEL are listed in the following
                            table:</p>
<a name="id_2239c364-4d51-41f4-867f-d75fdc628cba"></a><table width="600.000">
<caption><span>Table 1</span></caption>
<col align="center" width="33.0%">
<col align="center" width="34.0%">
<col align="center" width="33.0%">
<thead><tr class="Botrule First Last">
<td class="Lrule Rrule" align="center" valign="top"><span class="Bold">Maximum size of the area to be
                                            sealed using cannula</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Maximum size of the area to be
                                            sealed using compressed gas</span></td>
<td class="Rrule" align="center" valign="top"><span class="Bold">Required package size of
                                            TISSEEL</span></td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="center" valign="top">8
                                            cm<span class="Sup">2</span>
</td>
<td class="Rrule" align="center" valign="top">100
                                            cm<span class="Sup">2</span>
</td>
<td class="Rrule" align="center" valign="top">2 mL</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">16
                                            cm<span class="Sup">2</span>
</td>
<td class="Rrule" align="center" valign="top">200
                                            cm<span class="Sup">2</span>
</td>
<td class="Rrule" align="center" valign="top">4 mL</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="center" valign="top">40
                                            cm<span class="Sup">2</span>
</td>
<td class="Rrule" align="center" valign="top">500
                                            cm<span class="Sup">2</span>
</td>
<td class="Rrule" align="center" valign="top">10 mL</td>
</tr>
</tbody>
</table>
<p>It is recommended that every time a patient receives a
                            dose of TISSEEL, the name and batch number of the product are documented
                            in order to maintain a record of the batches used.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5cd272c6-da50-46ee-b624-7c7d951a61dd"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Preparation of TISSEEL Kit (Freeze-Dried)</h2>
<p class="First"><span class="Bold">During preparation of TISSEEL
                                        Kit:</span></p>
<p><span class="Bold">DO NOT EXPOSE TO TEMPERATURES ABOVE
                                        37°C</span></p>
<p><span class="Bold">DO NOT MICROWAVE</span><br><span class="Bold">DO NOT REFRIGERATE OR FREEZE AFTER
                                        RECONSTITUTION </span></p>
<p><span class="Bold">Do not use iodine or heavy metal
                                        containing preparations such as betadine for disinfection of
                                        vial stoppers. Allow alcohol-based disinfectants to
                                        evaporate before puncturing stopper.</span></p>
<p>Use separate syringes for reconstituting
                                    Sealer Protein and Thrombin solutions and for application to
                                    prevent premature clotting.</p>
<p>After
                                    reconstitution, the product must be used within 4
                                    hours.</p>
<p>TISSEEL Kit contains the following
                                    substances in four separate vials: </p>
<p>
                                    -Sealer Protein Concentrate (Human)</p>
<p>
                                    -<span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor Solution
                                    (Synthetic)</p>
<p> -Thrombin
                                    (Human)</p>
<p> -Calcium Chloride
                                    Solution</p>
<p>Freeze-dried Sealer Protein
                                    Concentrate and Thrombin are reconstituted in <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span>
                                    Inhibitor Solution and Calcium Chloride Solution, respectively.
                                    The Sealer Protein Solution and Thrombin Solution are then
                                    combined using the DUPLOJECT Preparation and Application System,
                                    or an equivalent delivery device cleared by FDA for use with
                                    TISSEEL, to form the Fibrin Sealant.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ec2622ca-fc11-4ddd-b8e2-51b4e923289c"></a><a name="section-2.1.1"></a><p></p>
<p class="First"><span class="Bold">Prewarming TISSEEL Kit with
                                                FIBRINOTHERM</span></p>
<p>If a FIBRINOTHERM device is not
                                            available, contact Baxter (1-800-423-2090) for
                                            assistance. See FIBRINOTHERM manual for complete
                                            operating instructions.</p>
<ol>
<li>Plug the FIBRINOTHERM Heating and Stirring Device
                                                into an electrical socket and activate the warmer
                                                (amber switch). Ensure that the stirring mechanism
                                                of the FIBRINOTHERM device is initially switched off
                                                (green switch).</li>
<li>Place all four vials from the TISSEEL Kit into the
                                                prewarmed wells of the FIBRINOTHERM, using the
                                                appropriately sized adapter rings, and allow the
                                                vials to warm for up to 5 minutes (room temperature
                                                product may take less time).</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eb52d727-3261-4e6d-93b2-9f16df4c32e8"></a><a name="section-2.1.2"></a><p></p>
<p class="First"><span class="Bold">Preparation of Sealer Protein
                                                Solution with FIBRINOTHERM</span></p>
<ol>
<li>Remove the flip-off caps from the vial containing
                                                the Sealer Protein Concentrate and the vial
                                                containing the <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor Solution,
                                                disinfect the rubber stoppers of both vials with a
                                                germicidal solution and allow to dry.</li>
<li>Transfer the <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor Solution into
                                                the vial containing the freeze-dried Sealer Protein
                                                Concentrate using the sterile reconstitution
                                                components provided with the DUPLOJECT Preparation
                                                and Application System, or an equivalent device
                                                cleared by FDA for use with TISSEEL (see directions
                                                provided with the device system for specific
                                                reconstitution instructions). Gently swirl the vial
                                                to ensure that the freeze-dried material is
                                                completely soaked.</li>
<li>Place the vial into the largest opening of the
                                                FIBRINOTHERM device with the appropriate adaptor.
                                                Switch on the stirrer (green switch) and allow the
                                                vial contents to stir until all Sealer Protein
                                                Concentrate is dissolved.</li>
<li>Reconstitution of the freeze-dried Sealer Protein
                                                Concentrate is complete as soon as no undissolved
                                                particles are visible. Otherwise, return the vial to
                                                the FIBRINOTHERM device and agitate for a few more
                                                minutes until the solution appears
                                                homogeneous.</li>
</ol>
<p><span class="Bold">Notes:</span></p>
<p> -Do not use the Sealer Protein
                                            Concentrate until it has fully dissolved. If the Sealer
                                            Protein Concentrate has not dissolved within 20 minutes
                                            using the FIBRINOTHERM device, discard the vial and
                                            prepare a fresh kit.</p>
<p> -If not used
                                            promptly, keep the Sealer Protein Solution at 37°C
                                            without stirring. To ensure homogeneity, switch on the
                                            stirrer of the FIBRINOTHERM device shortly before
                                            drawing up the solution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bc251cdb-30a2-41a3-9fc7-1a17ae9f0cee"></a><a name="section-2.1.3"></a><p></p>
<p class="First"><span class="Bold">Preparation of Thrombin
                                                Solution with FIBRINOTHERM</span></p>
<ol>
<li>Remove the flip-off caps from the vial containing
                                                Thrombin and the vial containing Calcium Chloride
                                                Solution, disinfect the rubber stoppers of both
                                                vials with a germicidal solution and allow to
                                                dry.</li>
<li>Transfer the contents of the vial with Calcium
                                                Chloride Solution into the vial containing the
                                                freeze-dried Thrombin using the sterile
                                                reconstitution components provided with the
                                                DUPLOJECT Preparation and Application System, or an
                                                equivalent device cleared by FDA for use with
                                                TISSEEL (see directions provided with the device
                                                system for specific reconstitution
                                                instructions).</li>
<li>Swirl briefly.</li>
<li>Place the vial into the adapted opening of the
                                                FIBRINOTHERM device.</li>
<li>Reconstitution of Thrombin is complete when all of
                                                the Thrombin concentrate is dissolved.</li>
<li>Keep the Thrombin Solution at 37°C until
                                                used.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b764c657-5e1c-4967-bd05-6a5f63aab145"></a><a name="section-2.1.4"></a><p></p>
<p class="First"><span class="Bold">Transferring to the Sterile
                                                Field</span></p>
<p>For transfer of the Sealer Protein
                                            Solution and the Thrombin Solution to the sterile field,
                                            the scrub nurse should withdraw the solutions while the
                                            circulating nurse holds the non-sterile vials. The
                                            solutions should be withdrawn slowly by firm constant
                                            <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> to reduce the risk of large air
                                            bubbles.</p>
<p>See <span class="Italics"><a href="#i4i_section_id_58eae001-4926-419b-ad77-d0f251206e68">DOSAGE AND ADMINISTRATION, Method of Application
                                                  (2.3)</a>.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c0e7aacb-281b-4a73-ac5d-18b6ce06b345"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Preparation of TISSEEL Pre-Filled Syringe (Frozen)</h2>
<p class="First"><span class="Bold">During preparation of TISSEEL
                                        (frozen):</span></p>
<p><span class="Bold">DO NOT EXPOSE TO TEMPERATURES ABOVE
                                        37°C</span><br><span class="Bold">DO NOT MICROWAVE</span><br><span class="Bold">DO NOT REFRIGERATE OR
                                        RE-FREEZE</span></p>
<p>Do not use TISSEEL (frozen) until it is
                                    completely thawed and warmed (liquid
                                    consistency).</p>
<p>Do not remove the protective
                                    syringe cap until use.</p>
<p>TISSEEL (frozen)
                                    can be prepared (thawed) using one of two options:</p>
<p><span class="Bold"><span class="Underline">Room Temperature
                                            Thawing</span></span></p>
<p>Unopened pouches may be stored for up to 48
                                    hours at room temperature (15-25°C). </p>
<p>When
                                    product is thawed at room temperature, warm to 33-37°C prior to
                                    use and use immediately. The total thawing and warming time
                                    cannot exceed 48 hours.</p>
<p><span class="Underline"><span class="Bold">Quick Thawing</span></span></p>
<p><span class="Underline">Option 1 – Thawing on the sterile
                                        field using a water bath</span></p>
<p>33°C to 37°C sterile water bath - transfer
                                    DUO set and the inner pouch to the sterile field, remove
                                    pre-filled syringe from inner pouch and place directly into
                                    sterile water bath. Ensure the contents of the pre-filled
                                    syringe are completely immersed under the
                                    water.</p>
<p>Approximate thawing and warming
                                    times when using this method are: </p>
<a name="id_cbe5fb72-d693-4813-b764-40a459c5e58c"></a><table width="600.000">
<col align="center" width="50.0%">
<col align="center" width="50.0%">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><span class="Bold">Pack Size</span></td>
<td class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Thawing/Warming Times<br>
                                                  33°C to 37°C Sterile Water Bath<br> (Pouches
                                                  Removed)</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule Toprule" align="center" valign="bottom">2 mL</td>
<td class="Rrule" align="center" valign="bottom">5
                                                minutes</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="bottom">4 mL</td>
<td class="Rrule" align="center" valign="bottom">5
                                                minutes</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="bottom">10 mL</td>
<td class="Botrule Rrule" align="center" valign="bottom">12 minutes</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b5afa531-3eb3-4141-9176-7483a5bad774"></a><a name="section-2.2.1"></a><p></p>
<p class="First"><span class="Underline">Option 2 – Thawing off
                                                the sterile field using a water bath</span></p>
<p>33°C to 37°C non-sterile water bath
                                            in two pouches - maintain the pre-filled syringe in both
                                            pouches and place into a water bath off the sterile
                                            field for appropriate time. Ensure the pouches remain
                                            submerged throughout thawing. Remove from the water bath
                                            after thawing, dry external pouch and transfer inner
                                            pouch with pre-filled syringe onto the sterile
                                            field.</p>
<p>Approximate thawing and
                                            warming times when using this method
                                            are:</p>
<a name="id_2eb3aaf1-fe2a-416a-b7a4-46e2a5ba7c0d"></a><table width="600.000">
<col align="center" width="50.0%">
<col align="center" width="50.0%">
<thead><tr class="Botrule First Last">
<td class="Lrule Rrule" align="center" valign="bottom"><span class="Bold">Pack Size</span></td>
<td class="Rrule" align="center" valign="bottom"><span class="Bold">Thawing/Warming
                                                  Times<br> 33°C to 37°C Non-Sterile Water
                                                  Bath<br> (In Pouches)</span></td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="center" valign="top">2 mL</td>
<td class="Rrule" align="center" valign="top">30 minutes</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">4 mL</td>
<td class="Rrule" align="center" valign="top">40 minutes</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="center" valign="top">10 mL</td>
<td class="Rrule" align="center" valign="top">80 minutes</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_92bf5a79-443e-4c8a-b9a6-db0d7b8630a2"></a><a name="section-2.2.2"></a><p></p>
<p class="First"><span class="Underline">Option 3 – Thawing off
                                                the sterile field using an incubator</span></p>
<p>33°C to 37°C incubator in pouches –
                                            maintain the pre-filled syringe in both pouches and
                                            place into an incubator for appropriate time. Remove
                                            from incubator after thawing and transfer inner pouch
                                            with pre-filled syringe onto the sterile
                                            field.</p>
<p>Approximate thawing and
                                            warming times when using this method are:
                                            </p>
<a name="id_e9877b92-b436-41e5-b4ad-dfbbb16f16f8"></a><table width="600.000">
<col align="center" width="50.0%">
<col align="center" width="50.0%">
<thead><tr class="Botrule First Last">
<td class="Lrule Rrule" align="center" valign="bottom"><span class="Bold">Pack Size</span></td>
<td class="Rrule" align="center" valign="bottom"><span class="Bold">Thawing/Warming
                                                  Times<br> 33°C to 37°C Incubator <br> (In
                                                  Pouches)</span></td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="center" valign="top">2 mL</td>
<td class="Rrule" align="center" valign="top">40 minutes</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">4 mL</td>
<td class="Rrule" align="center" valign="top">85 minutes</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="center" valign="top">10 mL</td>
<td class="Rrule" align="center" valign="top">105 minutes</td>
</tr>
</tbody>
</table>
<p>Maintain the product at 33-37°C until
                                            use. If the package is opened or warmed to 33-37°C it
                                            must be used within 4 hours.</p>
<p>See
                                                <span class="Italics"><a href="#i4i_section_id_58eae001-4926-419b-ad77-d0f251206e68">DOSAGE AND ADMINISTRATION, Method of Application
                                                  (2.3)</a>.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_58eae001-4926-419b-ad77-d0f251206e68"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Method of Application</h2>
<p class="First">Vials and pre-filled syringes are for single use only.
                                    Discard any unused product.</p>
<p>The <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span>
                                    surface should be as dry as possible before application.
                                    </p>
<p>Avoid application beyond the intended
                                    area.</p>
<p>Immediately before application,
                                    expel and discard the first several drops from the application
                                    cannula to ensure adequate mixing of the Sealer Protein and
                                    Thrombin solutions in cases where very small volumes (1-2 drops)
                                    of product are administered.</p>
<p>To prevent
                                    adherence, wet gloves with normal saline before product
                                    contact.</p>
<p>Apply TISSEEL as a thin layer.
                                    The initial amount of the product to be applied should be
                                    sufficient to entirely cover the intended application area. The
                                    application can be repeated, if necessary. If repeat application
                                    is necessary, reapply before polymerization takes place since
                                    TISSEEL may not adhere to a polymerized
                                    layer.</p>
<p>After the two components have been
                                    applied, fix or hold the sealed parts in the desired position
                                    for at least three to five minutes to ensure the setting TISSEEL
                                    adheres firmly to the surrounding tissue.
                                    </p>
<p>   </p>
<p><span class="Underline">TISSEEL Kit
                                        (Freeze-Dried)</span></p>
<p>Apply TISSEEL using the DUPLOJECT Fibrin
                                    Sealant Preparation and Application System or an equivalent
                                    delivery device cleared by FDA for use with TISSEEL. Specific
                                    instructions for the use of TISSEEL in conjunction with each
                                    cleared delivery device are provided with the device. </p>
<p><span class="Underline">TISSEEL Pre-filled Syringe
                                        (Frozen)</span></p>
<p>Apply pre-filled TISSEEL using the DUO Set
                                    accessory devices provided with the product or an equivalent
                                    delivery device cleared by FDA for use with TISSEEL.
                                    </p>
<p>DUO Set Instructions (see Figure 1
                                    below): </p>
<ol>
<li>Insert plunger into syringe barrel.</li>
<li>Firmly connect the two syringe nozzles to the joining
                                        piece and secure it by fastening the tether strap to the
                                        syringe.</li>
<li>Fit an application cannula to the joining piece. Apply by
                                        depressing plunger. </li>
</ol>
<p>Note: Interruption of TISSEEL application causes
                                    clogging in the cannula. Replace the cannula immediately prior
                                    to resuming application. If the opening of the joining piece (Y
                                    connector) facing the cannula is clogged, use the spare joining
                                    piece provided in the package.</p>
<div class="Figure">
<img alt="Figure 1 DUO SET Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e1aca067-0c96-4025-88bc-bd2345a46a30&amp;name=e1aca067-0c96-4025-88bc-bd2345a46a30-01.jpg"><p class="MultiMediaCaption">Figure 1
                                        DUO SET</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_5c7b91ff-820a-4edf-b3b1-83eba5bf6021"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0e83f45d-79a4-4325-b4cc-40edb5cb7978"></a><a name="section-3.1"></a><p></p>
<h2>3.1 Presentations and Pack Sizes</h2>
<p class="First">TISSEEL Kit (Freeze-Dried) is supplied as 2 mL, 4 mL
                                    and 10 mL (total volume) pack sizes with and without the
                                    DUPLOJECT Preparation and Application
                                    System.</p>
<p>TISSEEL Pre-filled Syringe
                                    (Frozen) is supplied as 2 mL, 4 mL and 10 mL (total volume) pack
                                    sizes with the DUO Set.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2e294a9f-58ee-45ba-bdb9-0a114a0f3135"></a><a name="section-3.2"></a><p></p>
<h2>3.2 Package Contents</h2>
<p class="First">TISSEEL Kit (Freeze-Dried) and TISSEEL Kit
                                    (Freeze-Dried) with DUPLOJECT System</p>
<ol>
<li>Sealer Protein Concentrate (Human), Vapor Heated,
                                        Solvent/Detergent Treated, Freeze-Dried, Sterile</li>
<li><span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor Solution (Synthetic),
                                        Sterile</li>
<li>Thrombin (Human), Vapor Heated, Solvent/Detergent Treated,
                                        Freeze-Dried, Sterile</li>
<li>Calcium Chloride Solution, Sterile</li>
<li>DUPLOJECT Preparation and Application System (if indicated
                                        on the carton)</li>
</ol>
<p><span class="Bold">TISSEEL Pre-Filled Syringe (Frozen)
                                        with DUO Set</span></p>
<ol>
<li>(1) Sealer Protein Solution, Vapor Heated,
                                        Solvent/Detergent Treated, Sterile</li>
<li>(2) Thrombin Solution, Vapor Heated, Solvent/Detergent
                                        Treated, Sterile</li>
<li>Sterile accessory devices (DUO Set: 1 plunger, 2 joining
                                        pieces and 4 application cannulas) are included with each
                                        pre-filled syringe</li>
</ol>
<p>The reconstituted solution or pre-filled syringe
                                    contains:</p>
<p>Sealer Protein
                                    Solution</p>
<a name="id_1049d778-7886-4332-b719-8a329e918b5c"></a><table width="500.000">
<col align="left" width="10.0%">
<col align="left" width="50.0%">
<col align="left" width="40.0%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" rowspan="4" valign="top"></td>
<td class="Toprule" align="left" valign="top">Total
                                                protein:</td>
<td align="left" valign="top">96 – 125 mg/mL</td>
</tr>
<tr>
<td align="left" valign="top">Fibrinogen:</td>
<td align="left" valign="top">67 – 106 mg/mL</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor
                                                (Synthetic): </td>
<td align="left" valign="top">2250 – 3750 KIU/mL</td>
</tr>
<tr class="Botrule Last"><td align="left" colspan="2" valign="top">Other
                                                ingredients include: human albumin, tri-sodium
                                                citrate, histidine, niacinamide, polysorbate 80 and
                                                water for injection (WFI).</td></tr>
</tbody>
</table>
<p>Thrombin Solution</p>
<a name="id_2460bfb7-ebd4-486d-999b-b384fa915907"></a><table width="500.000">
<col align="left" width="10.0%">
<col align="left" width="50.0%">
<col align="left" width="40.0%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>The
                                                  potency expressed in units is determined using a
                                                  clotting assay against an internal reference
                                                  standard for potency that has been calibrated
                                                  against the World Health Organization (WHO) Second
                                                  International Standard for Thrombin, 01/580.
                                                  Therefore, a unit (U) is equivalent to an
                                                  International Unit (IU).</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" rowspan="3" valign="top"></td>
<td class="Toprule" align="left" valign="top">Thrombin (Human):</td>
<td align="left" valign="top">400 – 625
                                                  units/mL<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
</tr>
<tr>
<td align="left" valign="top">Calcium Chloride:</td>
<td align="left" valign="top">36 – 44 µmol/mL</td>
</tr>
<tr class="Botrule Last"><td align="left" colspan="2" valign="top">Other
                                                ingredients include: human albumin, sodium chloride
                                                and water for injection (WFI).</td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_f827ed7a-02a3-49f8-864f-73af187845f3"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b31b17a2-f4c7-42d5-b496-1bb088cbc3fb"></a><a name="section-4.1"></a><p></p>
<h2>4.1 Intravascular Application</h2>
<p class="First"><span class="Bold">Do not inject TISSEEL directly into
                                        the circulatory system or into highly vascularized tissue.
                                        Intravascular application of TISSEEL can lead to
                                        intravascular coagulation, may result in life-threatening
                                        <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>, and may increase the likelihood and
                                        severity of acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> in susceptible
                                        patients <span class="Italics">(see <span class="Italics"><a href="#i4i_section_id_da1e38ce-e463-4a5b-bbd4-637b51720a5c">WARNINGS AND PRECAUTIONS, Use in Cardiopulmonary
                                                  Surgery (5.3)</a></span> and <a href="#i4i_section_id_209c0f34-db97-4340-aec9-f4bd8c853424">ADVERSE REACTIONS, Post Marketing
                                            (6.3)</a>).</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5b895abf-fa57-450c-8d28-8f650d8aab57"></a><a name="section-4.2"></a><p></p>
<h2>4.2 Aprotinin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">Do not use TISSEEL in individuals with a known
                                    <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to aprotinin <span class="Italics">(see
                                            <a href="#i4i_section_id_b37d90e7-1ad5-421f-86b7-210babca1e74">WARNINGS AND PRECAUTIONS,
                                            <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/Allergic/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span>
                                            (5.1)</a> and <a href="#i4i_section_id_26e45906-641b-4b8a-bff4-3f7c87c08981">ADVERSE REACTIONS, Overall Adverse Reactions
                                            (6.1)</a>).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_69caf6f5-999d-4cae-ac6b-2f19208074f2"></a><a name="section-4.3"></a><p></p>
<h2>4.3 Arterial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">Do not use TISSEEL for treatment of severe or brisk
                                    arterial or venous <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. In these situations, TISSEEL will
                                    be washed away in the flow of blood before hemostasis can be
                                    attained.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_0db6a401-4925-4601-8307-0d51b80d485f"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b37d90e7-1ad5-421f-86b7-210babca1e74"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/Allergic/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> or allergic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>
                                    may occur with the use of TISSEEL. Cases (&lt;1/10,000) have
                                    been reported in post marketing experience with Baxter's fibrin
                                    sealant <span class="Italics">(see <a href="#i4i_section_id_209c0f34-db97-4340-aec9-f4bd8c853424">ADVERSE REACTIONS, Post Marketing
                                        (6.3)</a>).</span> In specific cases, these
                                    reactions have progressed to severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. Such reactions
                                    may especially be seen if TISSEEL is applied repeatedly over
                                    time or in the same setting, or if systemic aprotinin has been
                                    administered previously. Even if the first treatment was well
                                    tolerated, this may not exclude the occurrence of an allergic
                                    reaction after a subsequent administration of TISSEEL or
                                    systemic aprotinin. Observed symptoms of allergic anaphylactic
                                    reactions to TISSEEL have included: <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>,
                                    <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>,
                                    <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>. Such
                                    reactions may also occur in patients receiving TISSEEL for the
                                    first time.</p>
<p>Aprotinin is included in
                                    TISSEEL for its antifibrinolytic properties.  Aprotinin, a
                                    monomeric polypeptide, is known to be associated with
                                    <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>. Even in the case of strict local
                                    application of aprotinin, there is a risk of anaphylactic
                                    reactions to aprotinin, particularly in the case of previous
                                    exposure (see <span class="Italics"><a href="#i4i_section_id_5b895abf-fa57-450c-8d28-8f650d8aab57"> CONTRAINDICATIONS, Aprotinin
                                            <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>(4.2))</a></span>. TISSEEL
                                    does not contain any substances of bovine
                                    origin.</p>
<p>Discontinue administration of
                                    TISSEEL in the event of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. Mild
                                    reactions can be managed with antihistamines. Severe hypotensive
                                    reactions require immediate intervention using current
                                    principles of <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> therapy. Remove remaining product from the
                                    application site.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b1a55fd6-28c1-46f0-8f3c-272f442f585c"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Application Precautions</h2>
<p class="First">Air or gas <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> has occurred with the use of spray
                                    devices employing pressure regulator to administer fibrin
                                    sealants. This event appears to be related to the use of the
                                    spray device at higher than recommended pressures and in close
                                    proximity to the tissue surface.</p>
<p>When
                                    applying TISSEEL using a spray device, be sure to use the
                                    pressure within the pressure range recommended by the spray
                                    device manufacturer. In the absence of a specific recommendation
                                    avoid using pressure above 20-25 psi. Do not spray closer than
                                    the distance recommended by the spray device manufacturer. In
                                    the absence of a specific recommendation avoid spraying closer
                                    than 10-15 cm from the surface of the tissue. When spraying
                                    TISSEEL, changes in blood pressure, pulse, oxygen saturation and
                                    end tidal CO<span class="Sub">2</span> should be monitored because of the
                                    possibility of occurrence of air or gas <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>. When using the
                                    EASYSPRAY device, or an equivalent spray device for open
                                    surgical procedures cleared by FDA, TISSEEL must not be sprayed
                                    in enclosed body areas and must be sprayed onto only visible
                                    application sites.</p>
<p>The sealer protein and
                                    thrombin solutions can be denatured by alcohol, iodine or heavy
                                    metal ions. If any of these substances have been used to clean
                                    the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> area, the area must be thoroughly rinsed before the
                                    application of TISSEEL.</p>
<p>Apply TISSEEL as a
                                    thin layer. Excess clot thickness may delay the natural <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span>
                                    healing process.</p>
<p>The safety and
                                    effectiveness of the combined use of TISSEEL with other
                                    biocompatible materials has not been evaluated in controlled
                                    clinical trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_da1e38ce-e463-4a5b-bbd4-637b51720a5c"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Use in Cardiopulmonary Surgery</h2>
<p class="First">Caution should be exercised to minimize the risk of
                                    inadvertent intravascular application when using TISSEEL in
                                    cardiopulmonary bypass surgeries (<span class="Italics">see <a href="#i4i_section_id_b31b17a2-f4c7-42d5-b496-1bb088cbc3fb">CONTRAINDICATIONS, Intravascular Application
                                            (4.1)</a> and <a href="#i4i_section_id_209c0f34-db97-4340-aec9-f4bd8c853424">ADVERSE REACTIONS, Post Marketing (6.3)</a>).
                                    </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e9d9d7e4-c1c0-4e84-8214-32fdb00431f8"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Use in Neurosurgical Procedures</h2>
<p class="First">The safety and effectiveness of TISSEEL used alone or
                                    in combination with biocompatible carriers in neurosurgical
                                    procedures or other surgeries involving confined spaces have not
                                    been evaluated, and its use in this setting is not approved by
                                    FDA <span class="Italics">(see <a href="#i4i_section_id_209c0f34-db97-4340-aec9-f4bd8c853424">ADVERSE REACTIONS, Post Marketing (6.3)</a> and
                                            <a href="#i4i_interactions_id_d9d2ede8-72f1-4937-bc55-5a8b53da7fca">DRUG INTERACTIONS (7)</a>).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d60755c3-08ff-400e-a3ae-83907fcefd74"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> Risk from Human Plasma</h2>
<p class="First">TISSEEL is made from human plasma. Products made from
                                    human plasma may contain infectious agents, such as viruses,
                                    that can cause disease. The risk that such products will
                                    transmit an infectious agent has been reduced by screening
                                    plasma donors for prior exposure to certain viruses, by testing
                                    for the presence of certain virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and by
                                    inactivating and removing certain viruses during the
                                    manufacturing process (<span class="Italics">see <span class="Italics"><a href="#i4i_section_id_947f995c-a434-4b77-a010-a8376d0ee613">CLINICAL PHARMACOLOGY, Other Clinical Pharmacology
                                                Information (12.4)</a></span>).</span> Despite these measures, such products
                                    can still potentially transmit disease. Because this product is
                                    made from human blood, it may carry a risk of transmitting
                                    infectious agents, e.g., viruses, and theoretically, the
                                    Creutzfeldt-Jakob disease (CJD) agent. This also applies to
                                    unknown or emerging viruses and other pathogens. The measures
                                    taken are considered effective for inactivation/removal of lipid
                                    enveloped viruses such as HIV, HBV, and HCV, and for the
                                    non-lipid enveloped virus such as HAV. These measures may be of
                                    limited value against small non-lipid enveloped viruses such as
                                    Parvovirus B19. Parvovirus B19 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may be serious for
                                    pregnant women (fetal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>) and for individuals with
                                    <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> or increased red blood cell turnover (e.g.,
                                    <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>) (see <span class="Italics"><a href="#i4i_info_patients_id_1e82806d-2c8e-42fe-9a8a-4e76ee78e85b"> PATIENT COUNSELING INFORMATION </a></span><span class="Italics">(<a href="#i4i_info_patients_id_1e82806d-2c8e-42fe-9a8a-4e76ee78e85b">17</a></span>)). ALL <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> thought by a physician possibly to
                                    have been transmitted by this product should be reported by the
                                    physician or other healthcare provider to Baxter Healthcare
                                    Corporation, telephone number 1-866-888-2472.
                                </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_a537a0e5-87e7-4f41-95c3-094b0ee7854c"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_26e45906-641b-4b8a-bff4-3f7c87c08981"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Overall Adverse Reactions</h2>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/Allergic/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span>:</span>
                                    <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> or allergic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> may occur.
                                    In isolated cases, these reactions have progressed to severe
                                    <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> (<span class="Italics">see <a href="#i4i_section_id_b37d90e7-1ad5-421f-86b7-210babca1e74">WARNINGS AND PRECAUTIONS,
                                            <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/Allergic/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span>
                                            (5.1)</a></span>). No adverse events of this type were reported during
                                    clinical trials. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8c48ab01-4fcf-46c5-a8f7-7a9fcf8ef341"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely
                                    varying conditions, adverse reaction rates observed in the
                                    clinical trials of a drug cannot be directly compared to rates
                                    in the clinical trials of another drug and may not reflect the
                                    rates observed in practice.</p>
<p>Increased
                                    D-Dimer levels have been observed during a clinical study in
                                    cardiovascular surgery <span class="Italics">(see
                                            <a href="#i4i_clinical_studies_id_a2c77a09-71cc-4ed9-812c-8fa6520b1b95">CLINICAL STUDIES (14)</a>),</span> but did
                                    not exceed values reported in the literature occurring after
                                    this type of surgery. Postoperatively increased D-Dimers may
                                    result at least partly from the degradation of Fibrin
                                    Sealant.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_209c0f34-db97-4340-aec9-f4bd8c853424"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Post Marketing</h2>
<p class="First">Because adverse reactions are reported voluntarily and
                                    the population is of uncertain size, it is not always possible
                                    to reliably estimate the frequency of these
                                    reactions.</p>
<p>Manifestations of
                                    <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> associated with the class
                                    of fibrin sealant/hemostatic products include: application site
                                    irritation, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>,
                                    <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>. There have
                                    been no reports of these reactions related to the specific use
                                    of TISSEEL.</p>
<p>The following adverse
                                    reactions have been reported in the post-marketing
                                    experience:</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">IMMUNE SYSTEM DISORDERS</span></span>:
                                    <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> and
                                    <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> and anaphylactic
                                    <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> have included fatal outcomes.<br><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">VASCULAR DISORDERS</span></span>:
                                    <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, including <span class="product-label-link" type="condition" conceptid="375557" conceptname="Cerebral embolism">cerebral artery embolism</span>
                                    and venous thrombotic <span class="product-label-link" type="condition" conceptid="443454" conceptname="Cerebral infarction">cerebral infarction</span> as a result of
                                    intravascular application<br><span class="Bold">SKIN AND SUBCUTANEOUS TISSUE
                                        DISORDERS</span>: <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span>
                                    healing, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">CARDIAC DISORDERS</span></span>:
                                    <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">RESPIRATORY DISORDERS</span></span>:
                                    <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">GASTROINTESTINAL DISORDERS</span></span>:
                                    <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></p>
<p><span class="Bold">GENERAL DISORDERS AND ADMINISTRATION
                                        SITE CONDITIONS:</span> <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span></p>
<p style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">Air embolism</span> associated with
                                        misapplication of fibrin sealant using the spray device,
                                        Class Effect: A post marketing fatality was reported in
                                        association with the use of another fibrin sealant when
                                        applied using a spray device. The case involved an attempt
                                        to stop active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> by applying the fibrin sealant using
                                        a spray device attached to a wall unit at a higher than
                                        recommended pressure for the spray device. In addition, the
                                        spray head was placed at a distance from the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> site
                                        that was closer than the recommended distance guidelines for
                                        the application of the sealant. The patient suffered a fatal
                                        <span class="product-label-link" type="condition" conceptid="4156949" conceptname="Air embolism">air embolism</span>.</span></p>
<p>There have been reports of serious adverse
                                    events such as <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> and other compressive complications
                                    possibly related to the use of fibrin sealants in combination
                                    with resorbable hemostatic agents. There have also been reports
                                    of fatalities following the misadministration of topical
                                    thrombin <span class="Italics">(see <span class="Italics"><a href="#i4i_section_id_e9d9d7e4-c1c0-4e84-8214-32fdb00431f8">WARNINGS AND PRECAUTIONS, Use in Neurosurgical
                                                Procedures (5.4)</a></span>)</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_d9d2ede8-72f1-4937-bc55-5a8b53da7fca"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Oxycellulose containing preparations may reduce the efficacy of
                            TISSEEL and should not be used as carrier
                            materials.</p>
<p>No formal interaction studies have been
                            performed. </p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_0aeddcfa-be8b-472a-82a9-66b96e923fbe"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_10b0ab9a-9a2b-4f87-a347-3a00e95983f4"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category C</span></p>
<p>Animal reproduction studies have not been
                                    conducted with TISSEEL. It is also not known whether TISSEEL can
                                    cause fetal harm when administered to a pregnant woman or can
                                    affect reproduction capacity. Some viruses, such as parvovirus
                                    B19, are particularly difficult to remove or inactivate at this
                                    time. Parvovirus B19 most seriously affects pregnant women
                                    (fetal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>). TISSEEL should be given to a pregnant woman
                                    only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_17f6838f-7638-4ee2-9613-4a4e00d9db1b"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human
                                    milk. Because many drugs are excreted in human milk, caution
                                    should be exercised when TISSEEL is administered to nursing
                                    mothers.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_9dc68ece-7dec-4be7-a101-f7ba59441928"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of TISSEEL in pediatric
                                    patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_a87f988b-a758-4287-be6e-d44892f40d3c"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In a Phase 3 clinical study of TISSEEL 71 out of 144
                                    subjects were 65 and over <span class="Italics">(see
                                            <a href="#i4i_clinical_studies_id_a2c77a09-71cc-4ed9-812c-8fa6520b1b95">CLINICAL STUDIES (14)</a>). </span>No overall
                                    differences in safety or effectiveness were observed between
                                    these subjects and younger subjects, and other reported clinical
                                    experience has not identified differences in responses between
                                    the elderly and younger patients, but greater sensitivity of
                                    some older individuals cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_9d8f0621-3190-4069-b46b-66b245e97c74"></a><a name="section-9"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">TISSEEL [Fibrin Sealant], Vapor Heated, Solvent Detergent
                            Treated, (TISSEEL) is a two-component fibrin sealant made from pooled
                            human plasma. When combined, the two components, Sealer Protein (Human)
                            and Thrombin (Human), mimic the final stage of the blood coagulation
                            cascade. </p>
<p><span class="Bold">Sealer Protein (Human)</span></p>
<p>Sealer Protein (Human) is a sterile, non-pyrogenic,
                            vapor-heated and solvent/detergent treated preparation made from pooled
                            human plasma. Sealer Protein (Human) is provided either as a
                            freeze-dried powder [Sealer Protein Concentrate (Human)] for
                            reconstitution with <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor Solution (Synthetic) or as a
                            finished frozen solution pre-filled into one side of a dual-chambered
                            syringe (1). The active ingredient in Sealer Protein (Human) is
                            fibrinogen. A <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor, Aprotinin (Synthetic) is included
                            in the Sealer Protein (Human) component to delay <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>. Aprotinin
                            (Synthetic) is manufactured by solid phase synthesis from materials
                            completely of non-human/non-animal origin.</p>
<p>To
                            obtain Sealer Protein (Human), cryoprecipitate derived from the plasma
                            is dissolved in buffer solution, solvent/detergent treated, vapor heat
                            treated, sterile filtered and either freeze-dried in vials or frozen in
                            pre-filled syringes.</p>
<p><span class="Bold">Thrombin (Human)</span></p>
<p>Thrombin (Human) is a sterile, non-pyrogenic,
                            vapor-heated and solvent/detergent treated preparation made from pooled
                            human plasma. Thrombin (Human) is also provided either as a freeze-dried
                            powder for reconstitution with Calcium Chloride Solution or as a
                            finished frozen solution pre-filled into one side of a dual-chambered
                            syringe (2).</p>
<p>Thrombin is prepared from plasma
                            through a series of separation and filtration steps followed by
                            incubation of the solution with calcium chloride to activate <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span>
                            to thrombin. The solution subsequently undergoes ultra/diafiltration,
                            vapor heat treatment, solvent/detergent treatment, sterile filtration
                            and is either freeze-dried in vials or frozen in pre-filled syringes.
                            </p>
<p>Sealer Protein (Human) and Thrombin (Human) are
                            made from pooled human plasma collected at US licensed collection
                            centers. The vapor heat and solvent/detergent treatment steps used in
                            the manufacturing process have been shown to be capable of significant
                            viral reduction. No procedure, however, has been shown to be completely
                            effective in removing viral infectivity from derivatives of human plasma
                                (<span class="Italics">see <a href="#i4i_section_id_947f995c-a434-4b77-a010-a8376d0ee613">CLINICAL PHARMACOLOGY, Other Clinical Pharmacology Information
                                    (12.4)</a> and <span class="Italics"><a href="#i4i_section_id_d60755c3-08ff-400e-a3ae-83907fcefd74">WARNINGS AND PRECAUTIONS, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> Risk from Human Plasma
                                        (5.5)</a></span>). </span></p>
<p>See <span class="Italics"><a href="#i4i_dosage_form_strength_id_5c7b91ff-820a-4edf-b3b1-83eba5bf6021">DOSAGE FORMS AND STRENGTHS (3)</a></span>.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_e3909bd9-38fb-441e-819e-d2b3e2f88ff8"></a><a name="section-10"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_d0a60fff-79dc-4d61-90ce-666063eac1d2"></a><a name="section-10.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Upon mixing Sealer Protein (Human) and Thrombin
                                    (Human), soluble fibrinogen is transformed into fibrin, forming
                                    a rubber-like <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> that adheres to the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> surface and
                                    achieves hemostasis and sealing or gluing of tissues.
                                </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_ca8460ca-6697-44e2-93d1-535f507da4e2"></a><a name="section-10.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Thrombin is a highly specific protease that transforms
                                    the fibrinogen contained in Sealer Protein (Human) into fibrin
                                    (see <span class="Italics"><a href="#i4i_pharmacokinetics_id_fa64662c-a23d-4582-9f0b-92dc8abcd35d">Pharmacokinetics (12.3)</a></span>). </p>
<p><span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor,
                                    Aprotinin (Synthetic), is a polyvalent protease inhibitor that
                                    prevents premature degradation of fibrin. Free Aprotinin and its
                                    metabolites have a half-life of 30 to 60 minutes and are
                                    eliminated by the kidney. Preclinical studies with different
                                    fibrin sealant preparations simulating the fibrinolytic activity
                                    generated by extracorporeal circulation in patients during
                                    cardiovascular surgery have shown that incorporation of
                                    aprotinin in the product formulation increases resistance of the
                                    fibrin sealant clot to degradation in a fibrinolytic
                                    environment.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_fa64662c-a23d-4582-9f0b-92dc8abcd35d"></a><a name="section-10.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Pharmacokinetic studies were not conducted. Because
                                    TISSEEL is applied only topically, systemic exposure or
                                    distribution to other organs or tissues is not
                                    expected.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_947f995c-a434-4b77-a010-a8376d0ee613"></a><a name="section-10.4"></a><p></p>
<h2>12.4 Other Clinical Pharmacology Information</h2>
<p class="First"><span class="Bold">Viral Clearance</span></p>
<p>The manufacturing procedure for TISSEEL
                                    includes processing steps designed to further reduce the risk of
                                    viral transmission. In particular, vapor heating and
                                    solvent/detergent treatment processes are included in the
                                    manufacturing of Sealer Protein Concentrate and Thrombin.
                                    Validation studies were conducted using samples drawn from
                                    manufacturing intermediates for each of the two human plasma
                                    derived components. These samples were spiked with stock virus
                                    suspensions of known titers followed by further processing under
                                    conditions equivalent to those in the respective manufacturing
                                    steps. </p>
<p>The virus reduction factors
                                    (expressed as log<span class="Sub">10</span>) of manufacturing steps for each
                                    of the viruses tested are shown in <a href="#id_2f1969e4-2f38-4161-9e78-07a30a3034cd">Table
                                        2</a>.</p>
<a name="id_2f1969e4-2f38-4161-9e78-07a30a3034cd"></a><table width="600.000">
<caption><span>Table 2
                                        Reduction Factors for Virus Removal and/or Inactivation
                                        Sealer Protein Component</span></caption>
<col align="left" width="40.0%">
<col align="center" width="10.0%">
<col align="center" width="10.0%">
<col align="center" width="10.0%">
<col align="center" width="10.0%">
<col align="center" width="10.0%">
<col align="center" width="10.0%">
<tfoot><tr class="Last"><td class="Botrule Lrule Rrule" align="left" colspan="7" valign="top">n.d. =
                                                not determined<br><span class="Bold">HIV-1</span>: Human
                                                <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus 1; <span class="Bold">HAV</span>: <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> A Virus; <span class="Bold">BVDV</span>: Bovine Viral
                                                <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> Virus, a model for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C Virus;
                                                  <span class="Bold">PRV</span>:
                                                Pseudorabies Virus, a model for lipid enveloped DNA
                                                viruses, among those is <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B Virus; <span class="Bold">MMV</span>: Mice Minute Virus,
                                                a model for B19V.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top">Manufacturing Step</td>
<td class="Botrule Rrule" align="center" colspan="6" valign="top">Mean Reduction Factors
                                                  [log<span class="Sub">10</span>] of Virus Tested</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">HIV-1</td>
<td class="Botrule Rrule" align="center" valign="top">HAV</td>
<td class="Botrule Rrule" align="center" valign="top">BVDV</td>
<td class="Botrule Rrule" align="center" valign="top">PRV</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">MMV</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Early Manufacturing Steps</td>
<td class="Botrule Rrule" align="center" valign="top">n.d.</td>
<td class="Botrule Rrule" align="center" valign="top">n.d.</td>
<td class="Botrule Rrule" align="center" valign="top">n.d.</td>
<td class="Botrule Rrule" align="center" valign="top">n.d.</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">2.7</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Solvent/Detergent Treatment</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;5.3</td>
<td class="Botrule Rrule" align="center" valign="top">n.d.</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;5.7</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;5.9</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">n.d.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Vapor Heat Treatment</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;5.5</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;5.6</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;5.7</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;6.7</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">1.2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Overall Reduction Factor (ORF)</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;10.8</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;5.6</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;11.4</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;12.6</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">3.9</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="7" valign="top">Reduction Factors for Virus Removal and/or
                                                Inactivation<br>Thrombin Component</td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="6" valign="top">Mean Reduction Factors
                                                  [log<span class="Sub">10</span>] of Virus Tested</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Manufacturing Step</td>
<td class="Botrule Rrule" align="center" valign="top">HIV-1</td>
<td class="Botrule Rrule" align="center" valign="top">HAV</td>
<td class="Botrule Rrule" align="center" valign="top">BVDV</td>
<td class="Botrule Rrule" align="center" valign="top">PRV</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">MMV</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Thrombin Precursor <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> Capture</td>
<td class="Botrule Rrule" align="center" valign="top">3.2</td>
<td class="Botrule Rrule" align="center" valign="top">1.5</td>
<td class="Botrule Rrule" align="center" valign="top">1.8</td>
<td class="Botrule Rrule" align="center" valign="top">2.5</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">1.2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Vapor Heat Treatment</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;5.5</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;4.9</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;5.3</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;6.7</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">1.0</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Solvent/Detergent Treatment</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;5.3</td>
<td class="Botrule Rrule" align="center" valign="top">n.d.</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;5.5</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;6.4</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">n.d.</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Ion Exchange Chromatography</td>
<td class="Botrule Rrule" align="center" valign="top">n.d.</td>
<td class="Botrule Rrule" align="center" valign="top">n.d.</td>
<td class="Botrule Rrule" align="center" valign="top">n.d.</td>
<td class="Botrule Rrule" align="center" valign="top">n.d.</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">3.6</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Overall Reduction Factor (ORF)</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;14.0</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;6.4</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;12.6</td>
<td class="Botrule Rrule" align="center" valign="top">&gt;15.6</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">5.8</td>
</tr>
</tbody>
</table>
<p>In addition, Human Parvovirus B19V was used to
                                    investigate the upstream Thrombin precursor <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> capture step,
                                    the Sealer Protein early manufacturing steps and the Thrombin
                                    and Sealer Protein vapor heating steps. Using quantitative PCR
                                    assays, the estimated log reduction factors obtained were 1.7
                                    and 3.4 for the Thrombin precursor <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> capture step and Sealer
                                    Protein early manufacturing steps and &gt;4 / 1.0 for the
                                    Thrombin / Sealer Protein vapor heating steps,
                                    respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_3e9ce497-5bf3-4303-b15d-b9a66ae376a5"></a><a name="section-11"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_5fb6d760-73bc-4c86-a242-00c50e99f092"></a><a name="section-11.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term animal studies to evaluate the carcinogenic
                                    potential of TISSEEL or studies to determine the effect of
                                    TISSEEL on fertility have not been performed.
                                </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_a2c77a09-71cc-4ed9-812c-8fa6520b1b95"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_df00ed76-8070-43b5-bd8e-5aad769e8052"></a><a name="section-12.1"></a><p></p>
<h2>14.1 Cardiac Surgery</h2>
<p class="First">TISSEEL was evaluated in a prospective, parallel
                                    design, randomized (1:1), double-blind, multicenter clinical
                                    study against an earlier formulation of the product, TISSEEL VH,
                                    in 317 subjects undergoing cardiac surgery requiring
                                    cardiopulmonary bypass (CPB) and median sternotomy. Patients
                                    were treated with TISSEEL or the control product only when
                                    hemostasis was not achieved by conventional surgical methods.
                                    For the endpoint, hemostasis achieved at the primary treatment
                                    site within 5 minutes of treatment and maintained until closure
                                    of the surgical <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span>, TISSEEL was non-inferior to the earlier
                                    formulation of the product using a one-sided 97.5% confidence
                                    interval on the difference in the proportion of subjects
                                    successfully treated.</p>
<a name="id_7f33154e-afa3-4abc-9f1f-0d773be6c2b4"></a><table width="600.000">
<caption><span>Table 3
                                        Hemostasis within 5 minutes and maintained until surgical
                                        closure</span></caption>
<col align="left" width="34.0%">
<col align="center" width="33.0%">
<col align="center" width="33.0%">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top">TISSEEL </td>
<td class="Botrule Rrule" align="center" valign="top">TISSEEL VH </td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">Intent to Treat Analysis</td>
<td class="Botrule Rrule" align="center" valign="top">127/144 (88.2%)</td>
<td class="Botrule Rrule" align="center" valign="top">129/144 (89.6%)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">Per Protocol Analysis</td>
<td class="Rrule" align="center" valign="top">108/123 (87.8%)</td>
<td class="Botrule Rrule" align="center" valign="top">122/135 (90.4%)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3494e50e-e8d0-41c5-b58c-0ee4d4c25adb"></a><a name="section-12.2"></a><p></p>
<h2>14.2 Cardiac Reoperations</h2>
<p class="First">An earlier formulation of TISSEEL was evaluated in an
                                    open-label crossover study against control topical hemostatic
                                    agents in 489 patients undergoing cardiovascular reoperation or
                                    resternotomy at 11 institutions. Patients were randomized to
                                    TISSEEL or control hemostatic agents when a topical hemostatic
                                    was needed at the conclusion of surgery and after all attempts
                                    at surgical hemostasis. Patients were crossed to the alternative
                                    therapy if <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> continued after the 5 minute endpoint. At 10
                                    centers, TISSEEL was used after administration of protamine
                                    sulfate. At one site, TISSEEL could be used before
                                    administration of protamine sulfate. 365 of the 489 patients
                                    developed <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes requiring treatment. For the
                                    endpoint (successful hemostasis at 5 minutes), TISSEEL was
                                    statistically significantly superior to control topical
                                    hemostatic agents in these patients. Similarly, absolute time to
                                    cessation of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> was statistically significantly shorter
                                    for TISSEEL than for control topical hemostatic agents
                                    (p&lt;0.0001, Gehan-Wilcoxon test, two sided).</p>
<a name="id_00325c90-5479-4e96-8e79-e9187b81bff5"></a><table width="600.000">
<caption><span>Table 4
                                        Hemostasis within 5 minutes</span></caption>
<col align="center" width="50.0%">
<col align="center" width="50.0%">
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">TISSEEL</td>
<td class="Botrule Rrule" align="center" valign="top">Control Topical Hemostatic Agent</td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">82.4% (159/193)</td>
<td class="Botrule Rrule" align="center" valign="top">44.5% (76/172)</td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top">Pearson
                                                  χ<span class="Sup">2</span> two sided; p &lt;0.0001;
                                                intent-to-treat analysis</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9151fa4a-14e4-4a9e-b8de-2a78749b0eb2"></a><a name="section-12.3"></a><p></p>
<h2>14.3 Splenectomy</h2>
<p class="First">In a single center, open label trial, an earlier
                                    formulation of TISSEEL was compared to historical controls in
                                    patients undergoing laparotomy for blunt or penetrating
                                    <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">traumatic injury</span> to the spleen and/or liver. Use of TISSEEL
                                    resulted in the need for statistically significantly fewer
                                    splenectomies than control hemostatic maneuvers (Refer to Table
                                    5). TISSEEL did not result in significantly reduced mortality in
                                    patients with blunt or penetrating <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> to the liver alone or
                                    to the liver and spleen (p=0.067, χ<span class="Sup">2</span>, one
                                    sided).</p>
<a name="id_1545ebf6-3a94-4fcb-a764-2a5ccf2e69b1"></a><table width="600.000">
<caption><span>Table 5
                                        Splenectomy Rate</span></caption>
<col align="center" width="25.0%">
<col align="center" width="25.0%">
<col align="center" width="25.0%">
<col align="center" width="25.0%">
<thead><tr class="Botrule First Last">
<td class="Lrule" align="center" valign="top">Injury
                                                to:</td>
<td align="center" valign="top">TISSEEL </td>
<td align="center" valign="top">Historic Controls</td>
<td class="Rrule" align="center" valign="top"></td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td class="Botrule Lrule" align="center" valign="top">Spleen</td>
<td class="Botrule" align="center" valign="top">0/19</td>
<td class="Botrule" align="center" valign="top">14/22</td>
<td class="Botrule Rrule" align="center" valign="top">p &lt;0.001</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule" align="center" valign="top">Spleen
                                                and liver</td>
<td align="center" valign="top">1/26</td>
<td align="center" valign="top">19/34</td>
<td class="Rrule" align="center" valign="top">p
                                                &lt;0.001</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_918f858c-c417-4223-86b4-56d8b2405635"></a><a name="section-12.4"></a><p></p>
<h2>14.4 Colostomy Closure</h2>
<p class="First">In a single center, prospective open label study of 120
                                    patients randomized to standard of care (59 patients) or
                                    standard of care plus fibrin sealant (61 patients) for elective
                                    colostomy closure after temporary colostomy placement for
                                    treatment of <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">traumatic injury</span> to the colon, the earlier version
                                    of TISSEEL plus standard of care was also shown to be
                                    significantly superior to standard of care alone (p=0.0406,
                                    Jonckheere-Terpstra test for ordinal data, two sided) with
                                    regard to anastomotic complications (leakage, intra-abdominal
                                    <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> formation, re-operation, <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>, and
                                    <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_9ff8bb8d-6593-40f0-a674-1fd8fee819a0"></a><a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">TISSEEL is supplied in the following pack sizes and
                            presentations:</p>
<a name="id_df209d97-1b3b-4c06-aa3c-464d52625152"></a><table width="600.000">
<caption><span>Table 6 NDC Number </span></caption>
<col align="center" width="25.0%">
<col align="center" width="25.0%">
<col align="center" width="25.0%">
<col align="center" width="25.0%">
<thead>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="middle"><span class="Bold">Pack Size</span></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="middle"><span class="Bold">TISSEEL Kit
                                            (Freeze-Dried)</span></td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="middle"><span class="Bold">TISSEEL Kit (Freeze-Dried) with
                                            DUPLOJECT System</span></td>
<td class="Botrule Rrule" align="center" valign="middle"></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" align="center" valign="middle"><span class="Bold">TISSEEL Pre-Filled Syringe
                                            (Frozen) with DUO Set</span></td></tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">2 mL</td>
<td class="Botrule Rrule" align="center" valign="middle">0944-4201-03</td>
<td class="Botrule Rrule" align="center" valign="middle">0944-4201-04</td>
<td class="Botrule Rrule" align="center" valign="middle">0944-8402-02</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="middle">4 mL</td>
<td class="Botrule Rrule" align="center" valign="middle">0944-4201-07</td>
<td class="Botrule Rrule" align="center" valign="middle">0944-4201-08</td>
<td class="Botrule Rrule" align="center" valign="middle">0944-8402-04</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="middle">10 mL</td>
<td class="Rrule" align="center" valign="middle">0944-4201-11</td>
<td class="Rrule" align="center" valign="middle">0944-4201-12</td>
<td class="Botrule Rrule" align="center" valign="middle">0944-8402-10</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_5a45a8e7-3209-4119-bcff-0c069d193aec"></a><a name="section-13.1"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<p><span class="Bold">TISSEEL Kit (Freeze-Dried)</span></p>
<p>Store at 2°C to 25°C. Avoid freezing. After
                                    reconstitution, the product must be used within 4 hours. Do not
                                    freeze or refrigerate reconstituted solutions.</p>
<p><span class="Bold">TISSEEL Pre-filled Syringe
                                        (Frozen)</span></p>
<a name="id_4a56b3b2-3216-4797-a265-4b4c743d37ef"></a><table width="600.000">
<col align="left" width="25.2%">
<col align="left" width="74.8%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top">Long term:</td>
<td align="left" valign="top">Store at ≤ -20°C.</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">Short term:</td>
<td align="left" valign="top">
<p class="First">Room Temperature Thawing: Unopened
                                                  pouches may be stored for up to 48 hours at room
                                                  temperature (15-25°C). </p>
<p>Quick Thawing: Maintain the product at
                                                  33-37°C until use. If the package is opened or
                                                  warmed to 33-37°C it must be used within 4
                                                  hours.</p>
<span class="Bold">Do not refrigerate or
                                                  re-freeze after thawing. Do not
                                                  microwave.</span>
</td>
</tr>
</tbody>
</table>
<p>Do not use after the expiration date. Discard if
                                    packaging of any components is damaged.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_1e82806d-2c8e-42fe-9a8a-4e76ee78e85b"></a><a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Because this product is made from human plasma, the physician
                            should discuss the risks and benefits of this product with the patient.
                            </p>
<p>Instruct patients to consult their physician if
                            symptoms of B19 virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> appear (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> and
                            <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span>) followed about two weeks later by a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>
                                (s<span class="Italics">ee <a href="#i4i_pregnancy_id_10b0ab9a-9a2b-4f87-a347-3a00e95983f4">USE IN SPECIFIC POPULATIONS, Pregnancy
                                (8.1)</a>).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b1bb03ab-d5fa-472a-9a87-0349f4e7fa47"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold">Baxter Healthcare Corporation</span><br>Westlake Village, CA 91362 USA<br>US License No.
                            140</p>
<p>This product is covered by US Patent No.
                            5,962,405.</p>
<p>Baxter, Duo, Duploject, Easyspray,
                            Fibrinotherm and Tisseel are trademarks of Baxter International Inc.
                        </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_b8af2db8-e015-431b-a5bb-ead594943649"></a><a name="section-16"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<img alt="TISSEEL 10 mL kit unit carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e1aca067-0c96-4025-88bc-bd2345a46a30&amp;name=e1aca067-0c96-4025-88bc-bd2345a46a30-02.jpg"><p class="MultiMediaCaption">TISSEEL 10 mL kit
                                unit carton</p>
</div>
<p class="First"><span class="Bold">Fibrin
                                Sealant</span></p>
<p><span class="Bold">TISSEEL </span></p>
<p><span class="Bold">10 mL</span></p>
<p>NDC 0944-4201-11</p>
<p>Vapor Heated,
                            Solvent/Detergent Treated,
                            Kit</p>
<p>Contents:</p>
<p><span class="Bold">Sealer Protein Concentrate</span> (Human), Vapor
                            Heated, Solvent/Detergent Treated, freeze dried, sterile, for 5 mL of
                            Sealer Protein Solution</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor Solution</span> (Synthetic), sterile,
                            3000 KIU of Aprotinin/mL</p>
<p><span class="Bold">Thrombin </span>(Human), Vapor Heated, Solvent/Detergent
                            Treated, freeze dried, sterile, for 5 mL of Thrombin Solution 500
                            units/mL</p>
<p><span class="Bold">Calcium
                                Chloride Solution</span>, sterile, 40
                            μmol/mL</p>
<p>The risks and benefits of this product
                            should be discussed with the patient. </p>
<p>Read
                            directions for reconstitution and application before use.
                            </p>
<p>Use within four hours of
                            reconstitution.</p>
<p><span class="Bold">NOT FOR
                                INJECTION.</span><span class="Bold">For single use only.</span></p>
<p>Latex free</p>
<p><span class="Bold">Rx Only</span></p>
<div class="Figure">
<img alt="Thrombin (Human) 5 mL vial label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e1aca067-0c96-4025-88bc-bd2345a46a30&amp;name=e1aca067-0c96-4025-88bc-bd2345a46a30-03.jpg"><p class="MultiMediaCaption">Thrombin (Human) 5
                                mL vial label</p>
</div>
<p><span class="Bold">Thrombin
                                (Human)</span></p>
<p>NDC 0944-7332-05</p>
<p>Vapor Heated,
                            Solvent/Detergent Treated, Freeze-Dried,
                            Sterile</p>
<p>Reconstitute with 5 mL of Calcium Chloride
                            Solution</p>
<p>Concentration: 500
                            units/mL</p>
<p>Use within 4 hours of
                            reconstitution.</p>
<p>Read enclosed directions prior to
                            use.</p>
<p><span class="Bold">NOT FOR
                                INJECTION.</span> Store at 2ºC to
                                25ºC.</p>
<p><span class="Bold">Baxter
                                Healthcare Corporation</span></p>
<p>Westlake Village, CA 91362
                            USA</p>
<p>U.S. License No. 140</p>
<p>Rx
                            only</p>
<div class="Figure">
<img alt="Calcium Chloride Solution 5 mL vial label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e1aca067-0c96-4025-88bc-bd2345a46a30&amp;name=e1aca067-0c96-4025-88bc-bd2345a46a30-04.jpg"><p class="MultiMediaCaption">Calcium Chloride
                                Solution 5 mL vial label</p>
</div>
<p><span class="Bold">Calcium Chloride
                                Solution</span></p>
<p>NDC
                            0944-7401-05</p>
<p>Sterile</p>
<p>For
                            reconstitution of freeze-dried Thrombin
                            (Human),</p>
<p>Contents: 5
                            mL</p>
<p>Concentration: 40 μmol/mL</p>
<p><span class="Bold">NOT FOR INJECTION.</span> Store at 2ºC to
                            25ºC.</p>
<p><span class="Bold">Baxter Healthcare
                                Corporation</span></p>
<p>Westlake Village, CA 91362
                            USA</p>
<p>U.S. License No. 140</p>
<p>Rx
                            only</p>
<div class="Figure">
<img alt="<span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor Solution (Synthetic) 5 mL vial label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e1aca067-0c96-4025-88bc-bd2345a46a30&amp;name=e1aca067-0c96-4025-88bc-bd2345a46a30-05.jpg"><p class="MultiMediaCaption"><span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span>
                                Inhibitor Solution (Synthetic) 5 mL vial label</p>
</div>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span>
                                Inhibitor Solution (Synthetic)</span></p>
<p>NDC
                            0944-7201-05</p>
<p>Sterile</p>
<p>For
                            reconstitution of freeze-dried Sealer Protein Concentrate
                            (Human),</p>
<p>Contents: 5
                            mL</p>
<p>Concentration: 3000 KIU of
                            Aprotinin/mL</p>
<p><span class="Bold">NOT FOR INJECTION. </span>Store at 2ºC to
                            25ºC.</p>
<p><span class="Bold">Baxter Healthcare Corporation</span></p>
<p>Westlake Village, CA 91362
                            USA</p>
<p>U.S. License No. 140</p>
<p>Rx
                            only</p>
<div class="Figure">
<img alt="Sealer Protein Concentrate (Human) 5 mL vial label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e1aca067-0c96-4025-88bc-bd2345a46a30&amp;name=e1aca067-0c96-4025-88bc-bd2345a46a30-06.jpg"><p class="MultiMediaCaption">Sealer Protein
                                Concentrate (Human) 5 mL vial label</p>
</div>
<p><span class="Bold">Sealer Protein
                                Concentrate (Human)</span></p>
<p>NDC 0944-7112-05</p>
<p>Vapor Heated,
                            Solvent/Detergent Treated, Freeze-Dried,
                            Sterile</p>
<p>Reconstitute with 5 mL of <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span>
                            Inhibitor Solution (Synthetic)</p>
<p>Vial contains a
                            stirrer to facilitate reconstitution.</p>
<p>Use within 4
                            hours of reconstitution.</p>
<p>Read enclosed directions
                            prior to use.</p>
<p><span class="Bold">NOT FOR INJECTION.</span> Store at 2ºC to
                            25ºC.</p>
<p><span class="Bold">Baxter Healthcare Corporation</span></p>
<p>Westlake Village, CA 91362
                            USA</p>
<p>U.S. License No. 140</p>
<p>Rx
                            only</p>
<p> </p>
<div class="Figure">
<img alt="TISSEEL 10 mL kit with Duploject sleeve" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e1aca067-0c96-4025-88bc-bd2345a46a30&amp;name=e1aca067-0c96-4025-88bc-bd2345a46a30-07.jpg"><p class="MultiMediaCaption">TISSEEL 10 mL kit
                                with Duploject sleeve</p>
</div>
<p><span class="Bold">Fibrin
                                Sealant</span></p>
<p><span class="Bold">TISSEEL </span></p>
<p><span class="Bold">10 mL</span></p>
<p>NDC 0944-4201-12</p>
<p>Vapor Heated,
                            Solvent/Detergent Treated,
                            Kit</p>
<p>Contents:</p>
<p><span class="Bold">Sealer Protein Concentrate</span> (Human),
                            Vapor Heated, Solvent/Detergent Treated, freeze dried, sterile, for 5 mL
                            of Sealer Protein Solution</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">Fibrinolysis</span> Inhibitor Solution</span>
                            (Synthetic), sterile, 3000 KIU of Aprotinin/mL</p>
<p><span class="Bold">Thrombin </span>(Human), Vapor Heated,
                            Solvent/Detergent Treated, freeze dried, sterile, for 5 mL of Thrombin
                            Solution 500 units/mL</p>
<p><span class="Bold">Calcium Chloride Solution</span>, sterile,
                            40 μmol/mL</p>
<p>The risks and benefits of this product
                            should be discussed with the patient. </p>
<p>Read
                            directions for reconstitution and application before use.
                            </p>
<p>Use within four hours of
                            reconstitution.</p>
<p><span class="Bold">NOT FOR
                                INJECTION.</span><span class="Bold">For single use only.</span></p>
<p>Latex free</p>
<p>Rx
                                Only</p>
<p><span class="Bold">Also includes:
                                DUPOLJECT Fibrin Sealant Preparation and Application System 10
                                mL</span></p>
<div class="Figure">
<img alt="Duploject 10 mL unit carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e1aca067-0c96-4025-88bc-bd2345a46a30&amp;name=e1aca067-0c96-4025-88bc-bd2345a46a30-08.jpg"><p class="MultiMediaCaption">Duploject 10 mL
                                unit carton</p>
</div>
<p><span class="Bold">DUPLOJECT </span></p>
<p><span class="Bold">10 mL</span></p>
<p><span class="Bold">Fibrin Sealant Preparation
                                and Application System</span></p>
<p>BAXTER, DUPLOJECT and TISSEEL are trademarks of
                            Baxter International Inc., registered in the U.S. Patent and Trademark
                            office.</p>
<p><span class="Bold">Reorder Number:
                                3400233</span></p>
<p>Manufactured for:</p>
<p><span class="Bold">Baxter Healthcare Corporation</span></p>
<p>Westlake Village, CA 91362
                            USA</p>
<p> </p>
<p> </p>
<p> </p>
<p> </p>
<p> </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TISSEEL 		
					</strong><br><span class="contentTableReg">fibrinogen human and thrombin human kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-4201</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-4201-12</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">0 VIAL, GLASS </td>
<td class="formItem">1 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">0 VIAL, GLASS </td>
<td class="formItem">1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 3</strong></td>
<td class="formItem">0 VIAL, GLASS </td>
<td class="formItem">1 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 4</strong></td>
<td class="formItem">0 VIAL, GLASS </td>
<td class="formItem">1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>SEALER PROTEIN CONCENTRATE HUMAN 		
					</strong><br><span class="contentTableReg">fibrinogen human powder, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-7112</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FIBRINOGEN</strong> (FIBRINOGEN) </td>
<td class="formItem">FIBRINOGEN</td>
<td class="formItem">90 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALBUMIN (HUMAN)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HISTIDINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>NIACINAMIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRISODIUM CITRATE DIHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-7112-05</td>
<td class="formItem">5 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103980</td>
<td class="formItem">02/18/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>THROMBIN HUMAN 		
					</strong><br><span class="contentTableReg">thrombin human powder, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-7332</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>THROMBIN HUMAN</strong> (THROMBIN HUMAN) </td>
<td class="formItem">THROMBIN HUMAN</td>
<td class="formItem">500 [iU]  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALBUMIN (HUMAN)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-7332-05</td>
<td class="formItem">5 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103980</td>
<td class="formItem">02/18/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 3 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong><span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">FIBRINOLYSIS</span> INHIBITOR SOLUTION 		
					</strong><br><span class="contentTableReg">aprotinin liquid</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-7201</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>APROTININ</strong></td>
<td class="formItem">3000 [iU]  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-7201-05</td>
<td class="formItem">5 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103980</td>
<td class="formItem">02/18/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 4 of 4</td></tr>
<tr><td class="contentTableTitle">
<strong>CALCIUM CHLORIDE SOLUTION 		
					</strong><br><span class="contentTableReg">calcium chloride liquid</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0944-7401</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM CHLORIDE</strong></td>
<td class="formItem">40 umol  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0944-7401-05</td>
<td class="formItem">5 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103980</td>
<td class="formItem">02/18/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103980</td>
<td class="formItem">02/18/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Baxter Healthcare Corporation
							(039121363)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Baxter Aktiengesellschaft</td>
<td class="formItem"></td>
<td class="formItem">300434670</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e1aca067-0c96-4025-88bc-bd2345a46a30</div>
<div>Set id: e1aca067-0c96-4025-88bc-bd2345a46a30</div>
<div>Version: 1</div>
<div>Effective Time: 20101008</div>
</div>
</div> <div class="DistributorName">Baxter Healthcare Corporation</div></p>
</body></html>
